GlassScriptPhysician profile
Michelle Leigh Endicott
NPI 1699774315
$3,514.29
in general payments reported to CMS, 2019-2025
21 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $15.71 · 2021: $207 · 2022: $529 · 2023: $1,030 · 2024: $625 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.49 |
| Education | $143.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,093.66 | 2021-2025 | |
| Janssen Biotech, INC. | $463.55 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $435.52 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $426.93 | 2019-2025 | Dupixent |
| Ucb, INC. | $253.46 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $227.71 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $169.87 | 2022-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $99.75 | 2022-2023 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $61.51 | 2023-2025 | |
| Amgen INC. | $60.99 | 2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $42.08 | 2023 | Sotyktu |
| Hill Dermaceuticals, INC. | $34.74 | 2025 | Tolak |
| Janssen Pharmaceuticals, INC | $26.34 | 2025 | Tremfya |
| Genzyme Corporation | $25.83 | 2023 | |
| Leo Pharma INC. | $21.27 | 2023 | Adbry |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $17.91 | 2025 | Opzelura |
| Pfizer INC. | $17.34 | 2024 | |
| Allergan, INC. | $16.64 | 2021 | |
| Prugen, INC. Pharmaceuticals | $11.07 | 2019 | |
| Organon LLC | $5.78 | 2025 | Vtama |
| Biofrontera INC. | $2.34 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Endicott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.